JP2004532896A - Ｉ型糖尿病の診断及び治療 - Google Patents

Ｉ型糖尿病の診断及び治療 Download PDF

Info

Publication number
JP2004532896A
JP2004532896A JP2003507548A JP2003507548A JP2004532896A JP 2004532896 A JP2004532896 A JP 2004532896A JP 2003507548 A JP2003507548 A JP 2003507548A JP 2003507548 A JP2003507548 A JP 2003507548A JP 2004532896 A JP2004532896 A JP 2004532896A
Authority
JP
Japan
Prior art keywords
compound
amino acid
group
diabetes
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003507548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532896A5 (enExample
Inventor
タン、ルサング
バーシェア、ブルース、シー．
ジャクリーン トルドー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JP2004532896A publication Critical patent/JP2004532896A/ja
Publication of JP2004532896A5 publication Critical patent/JP2004532896A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2003507548A 2001-06-22 2002-06-25 Ｉ型糖尿病の診断及び治療 Pending JP2004532896A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29975401P 2001-06-22 2001-06-22
PCT/CA2002/000975 WO2003001204A2 (en) 2001-06-22 2002-06-25 Type 1 diabetes diagnostics and therapeutics

Publications (2)

Publication Number Publication Date
JP2004532896A true JP2004532896A (ja) 2004-10-28
JP2004532896A5 JP2004532896A5 (enExample) 2006-01-05

Family

ID=23156146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003507548A Pending JP2004532896A (ja) 2001-06-22 2002-06-25 Ｉ型糖尿病の診断及び治療

Country Status (5)

Country Link
US (1) US20050129617A1 (enExample)
EP (1) EP1399740A2 (enExample)
JP (1) JP2004532896A (enExample)
CA (1) CA2449990A1 (enExample)
WO (1) WO2003001204A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018512411A (ja) * 2015-03-20 2018-05-17 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479482B2 (en) * 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
EP1846438A2 (en) * 2005-01-31 2007-10-24 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
DK2131856T3 (da) * 2007-03-07 2014-12-15 Uti Limited Partnership Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20140068487A1 (en) * 2012-09-05 2014-03-06 Roche Diagnostics Operations, Inc. Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
US8993008B1 (en) 2013-12-16 2015-03-31 Umm Al-Qura University Herbal composition for treating diabetes
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN111741746A (zh) 2017-11-29 2020-10-02 乌第有限合伙公司 治疗自身免疫性疾病的方法
CN108152503A (zh) * 2017-12-19 2018-06-12 上海澜帆实业有限公司 酶联免疫斑点印迹的自身免疫检测试剂盒及其操作流程

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
EP1094828A4 (en) * 1998-05-07 2005-01-26 Univ California USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS
AU7033400A (en) * 1999-08-30 2001-03-26 Jehad Mikhaiel Charo Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018512411A (ja) * 2015-03-20 2018-05-17 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド

Also Published As

Publication number Publication date
WO2003001204A3 (en) 2003-05-30
CA2449990A1 (en) 2003-01-03
WO2003001204A2 (en) 2003-01-03
US20050129617A1 (en) 2005-06-16
EP1399740A2 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
CN105079781B (zh) 用于治疗乳糜泻的组合物和方法
PT2059256T (pt) Péptidos imunogénicos e a sua utilização em distúrbios imunológicos
JP3445917B2 (ja) 抗原特異的活性化ｔ細胞
RU2761653C2 (ru) Пептиды и способы для лечения диабета
JP2010532785A (ja) 炎症性疾患および自己免疫疾患の治療および予防
JP2004532896A (ja) Ｉ型糖尿病の診断及び治療
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
CA2920321C (en) Peptides derived from thyroid stimulating hormone receptor useful in the prevention and/or treatment of graves' disease
HUT77047A (hu) Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
JP2015505315A (ja) 部分的ｍｈｃコンストラクト及びその使用方法
WO1996012737A9 (en) Compositions and treatment for multiple sclerosis
KR20040108650A (ko) 미엘린 염기성 단백질 기원의 면역허용원 펩타이드
US20070129307A1 (en) Insulin epitopes for the treatment of type 1 diabetes
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
CA2623391A1 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
US7601801B2 (en) HLA-A24 binding cancer antigen peptide derived from livin
JPH10501791A (ja) クラスｉｍｈｃペプチドによる細胞傷害性ｔ細胞リンパ球（「ｃｔｌ」）活性の調節
WO2014176604A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
AU2003232751A1 (en) Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
JP2023525276A (ja) 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
RU2689552C2 (ru) Новая иммунотерапевтическая композиция и ее применения
AU2020347906B2 (en) Proinsulin peptides for Type 1 Diabetes
US20090118173A1 (en) Treatment and prevention of inflammatory bowel diseases
AU2002344889A1 (en) Type 1 diabetes diagnostics and therapeutics
JPH10506098A (ja) 自己免疫疾患の処置のために有用なインバリアント鎖組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111